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Abstract 
The presence of ultrasound-induced cavitation in sonodynamic therapy (SDT) treatments 
has previously enhanced the activity and delivery of certain sonosensitisers in biological 
systems. The purpose of this work was to investigate the potential for two novel anti-cancer 
agents from natural derivatives, sanguinarine and ginger root extract (GRE), as 
sonosensitisers in an SDT treatment with in vitro PANC-1 cells. Both anti-cancer compounds 
had a dose-dependent cytotoxicity in the presence of PANC-1 cells. A range of six discreet 
ultrasound power-frequency configurations were tested and it was found that the cell death 
caused directly by ultrasound was likely due to the sonomechanical effects of cavitation. 
Combined treatment used dosages of 100 μM sanguinarine or 1mM of GRE with 15 s 
sonication at 500 kHz and 10 W. The sanguinarine-SDT and GRE-SDT treatments showed a 
6% and 17% synergistic increase in observed cell death, respectively. Therefore both 
sangunarine and GRE were found to be effective sonosensitisers and warrant further 
development for SDT, with a view to maximising the magnitude of synergistic increase in 
toxicity. 
Keywords: Sonodynamic therapy, pancreatic cancer, sonosensitiser, sanguinarine, ginger 
root extract. 
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public, commercial or not-for-profit sectors. 
 
  
2    
1 Introduction 
A particularly promising application of ultrasound technology in the field of human 
therapeutics is the developing cancer treatment modality ‘sonodynamic therapy’ (SDT), a 
technique that has seen success across numerous in vitro and in vivo studies [1, 2, 3]. SDT 
involves the combined use of ultrasound-induced cavitation in the presence of a chemical 
agent known as a ‘sonosensitiser’, with the resulting cellular damage and cytotoxicity being 
synergistically greater than the additive effects of each element alone. This may occur via 
chemical augmentation of the drug activity and/or via the enhanced accessibility of the cells 
via ultrasonically induced mechanical effects such as sonoporation or mechanical damage. 
By inducing cavitation in close proximity to the tumour mass, this approach offers a less 
invasive but more targeted treatment than is achievable with conventional cancer therapies, 
and could support much-needed progress in the battle against the most aggressive human 
cancers. 
By 2012 pancreatic cancer was ranked the twelfth most common human cancer by 
incidence rate, representing 2.4% of new cases worldwide [4]. Specifically, pancreatic ductal 
adenocarcinoma (PDAC) accounts for 90% of all pancreatic cancers and has an associated 
median survival rate of 4.6 months in Europe, making it the fourth leading cause of cancer-
related deaths on the continent and in the United States [5, 6]. More recent estimates 
suggest that pancreatic cancer could become the United States’ second leading cause of 
cancer-related deaths by the year 2030 [7]. PDAC is therefore the subject of the National 
Cancer Institute’s (NCI) first scientific framework for progress against recalcitrant cancers, 
which focuses on advancing effective therapeutics for this disease [8]. 
The main difficulty in treating human PDAC is due to its considerable resistance to 
conventional cancer therapies [8]. A key contributor to this resistance is the central 
anatomical location of the pancreas, where surrounding vital organs restrict direct access to 
the tumour site for treatment via surgical resection. Further, PDAC tumours have a 
characteristic tendency to manipulate the tumour microenvironment, resulting in high 
interstitial fluid pressures, increased production of extra-cellular matrix (ECM) proteins, 
desmoplasia, and weak tumour vasculature [8, 9]. The combination of these factors renders 
the conventional intravenous delivery of chemotherapeutic drugs largely ineffective, and 
suggests that a more targeted modality such as SDT would be a good therapeutic fit for the 
treatment of pancreatic cancer. 
Chemical compounds derived from natural sources are commonly tested for anti-cancer 
properties as part of the search for new chemotherapy treatments. Two such compounds, 
namely the plant alkaloid sanguinarine (found in the Bloodroot plant sanguinaria canadensis) 
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and ginger root extract (GRE) (zingiber officinale roscoe), have both been reported to exhibit 
significant anti-cancer effects against several human cancer cell lines in vitro and in vivo [10, 
11, 12, 13]. These naturally-derived compounds have the general advantage of being 
relatively abundant and have potential to cause fewer unwanted side effects in patients, 
when compared to synthetic chemotherapeutic agents. Specifically, sanguinarine (Figure 1a) 
has been shown to induce cell death via apoptosis [11] which occurs along pathways that 
interact with both cell internal and membrane functions [12]. Though the major active 
components of GRE (widely accepted to be [6]-shogaol and [6]-gingerol; Figures 1b, 1c) 
have demonstrated an ability to induce apoptosis in various cell lines when used in isolation 
[14, 15, 16], the GRE mixture has been shown to induce cell death via autosis with PANC-1 
cells [13]. Across these studies, an accumulation of cells in the G0/G1 phase cell cycle was 
observed regardless of the predominant cell death mechanism, indicating the two 
substances share the anti-proliferative properties that are desirable in proven 
chemotherapeutic agents. 
While the development of sanguinarine and GRE as anti-cancer drugs remains immature, 
the aforementioned cytotoxic effects are understood to result from each compound’s ability 
to generate reactive oxygen species (ROS) which damage cell mitochondria [11, 12, 13]. 
The generation of ROS is also a common sonochemical effect of collapsing cavitation 
microbubbles, and is one of the primary mechanisms by which SDT treatments are made 
more potent. It therefore follows that both compounds are viable candidate sonosensitisers 
for a novel SDT treatment for pancreatic cancer.  
The focus of the present work is hence to investigate the extent of any synergistic increase 
in the cytotoxic effects of these novel SDT treatments using sanguinarine and GRE, when 
administered to in vitro PANC-1 cells (i.e. any reduction in cell viability that is greater than 
the sum of that caused by the ultrasound and either compound alone). Given the reported 
anti-cancer properties of these two candidate compounds, ultrasound could further augment 
the toxicity of the sonosensitisers, and/or benefit from enhanced accessibility via mechano-
acoustic effects. In order to understand the potential mechanisms of interaction between the 
ultrasound and the therapeutic agents, initial ultrasonic calibrations and toxicity testing were 
performed. The combined approach presents a unique way of developing SDT, enabling a 
mechanistic elucidation of the treatment fundamentals, which allows for a more informed and 
targeted follow-on approach. This involved confirming the reported toxicity of both 
compounds with this particular cancerous cell line, before testing a range of ultrasound 
parameter combinations to ensure the presence of acoustic cavitation in the setup. PANC-1 
cells were chosen as the cell line is widely regarded as a primary tumour for in vitro PDAC 
model [17]. PANC-1 has been found to be resistant to conventional chemotherapy  [18] and 
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more aggressive with a greater metastatic potential than two other commercially available 
pancreatic cancer cell lines [17]. Analysis of these results then informed the design and 
configuration of the main combined treatment study. Any indication of a synergistic increase 
in toxicity would be a significant benefit to the treatment modality as it would allow a 
relatively low dosage of sonosensitiser to be used with eventual in vivo subjects, thereby 
minimising any unwanted cell damage in surrounding healthy tissue. 
 
2 Materials and Methods 
2.1 Chemicals and Consumables 
Sanguinarine chloride hydrate in solid powdered form (CAS No. 5578-73-4; 98% HPLC 
purity), ginger root extract (GRE) in liquid form (CAS No. 84696-15-1; Food grade), and 
dimethyl sulphoxide (DMSO; CAS No. 67-68-5; 99.7% purity) were obtained from Sigma 
Aldrich (Poole, UK). PANC-1 cells (PDAC cells derived from a 56-year old Caucasian male) 
were obtained from Sigma Aldrich (Poole, UK). Dulbecco’s Modified Eagle’s Medium 
(DMEM), Modified Dulbecco’s Phosphate Buffered Saline (DPBS), Trypsin, 
Ethylenediaminetetraacetic acid (EDTA), L-glutamine and penicillin-streptomycin were 
obtained from Sigma Aldrich (Poole, UK). Fetal Bovine Serum (FBS) was purchased from 
Gibco Life Technologies and the CellTiter 96® MTS assay kit was supplied by Promega 
(Southampton, UK). Potassium iodide in powdered form (CAS No. 7681-11-0; 99% purity) 
was supplied by Fisher Scientific (Loughborough, UK). 
 
2.2 Cell Culturing and Treatment 
The adherent PANC-1 cells were cultured in Nunc™ T-75 flasks using DMEM supplemented 
with 10% FBS; 1% L-glutamine; 1% penicillin-streptomycin. PANC-1 cultures were 
maintained under standard conditions (37oC; 5% CO2) in a humidified incubator. Cultures 
were harvested via trypsinisation and centrifugation using DPBS and EDTA with 2.5% 
Trypsin, before being transferred to Nunc™ T-25 flasks / Nunc™ 96-well plates as required. 
Cell counting was conducted using a hemocytometer and desired cell densities were 
subsequently calculated. 
 
2.3 Natural Compound Screening Study 
Two consecutive screening studies were conducted to confirm the reported cytotoxic effects 
of sanguinarine and GRE when administered to PANC-1 cells [10, 11, 12, 13], and 
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subsequently determine appropriate dosages for use in the combined treatment study. 
Quantitative assessment of cell viability took place using MTS proliferation assay in 
conjunction with a BioTek Synergy HT plate reader and Gen5 computer software. 
10 mM stock solutions of sanguinarine and GRE in DMSO were prepared and further diluted 
with supplemented DMEM solution to the desired dosages. Across both screening studies 
the tested dosages ranged from 0.5-20.0 µM for sanguinarine and 1.0-100 µM for GRE in 
accordance with other published works [10, 13], with the second study testing a narrower 
range of dosages as prompted by the results of the first. PANC-1 cells were plated in a 96-
well plate at a seed density of 4,000 cells/well with 200 µL/well supplemented DMEM 
solution. Cells were incubated for 24 hours prior to drug dosing to allow cells to detach. Each 
well was dosed with 200 µL of either sanguinarine- or GRE-supplemented DMEM solution at 
the required concentration. Cell viability measurements were recorded 24, 48 and 72 hours 
after dosing using 120 µL/well MTS in supplemented DMEM solution according to the 
manufacturer’s instructions (dilution factor of 6), with plates incubated for 3 hours. All 
reported results represent the mean and standard deviation of four experiments.  
 
2.4 Ultrasound Calibration Study 
A number of preliminary tests were carried out to confirm the presence of acoustic cavitation 
within the experimental set up used in this investigation. For sonication experiments a T&C 
Power Conversion Inc. AG 1006 Amplifier/Generator was used in conjunction with one of 
two electrically-driven piezoceramic plate transducers, with resonance frequencies of 500 
kHz and 1.0 MHz. Each of these tests were conducted using six different power-frequency 
configurations: 500 kHz, 10/20/30 W and 1.0 MHz, 20/30/40 W. A schematic of the 
equipment configuration used is shown at Figure 2.  
The first of these tests determined the discrepancy between the incident ultrasound power 
as set using the amplifier, and the power received by the liquid in the submerged T-25 flask 
as measured calorimetrically. This was calculated in accordance with an established method 
[19] with temperature readings taken at 15 s intervals. The second test also followed an 
established dosimetric method [19] to determine the extent of radical species formation 
during sonication. 
The concentration of tri-iodide ions in the T-25 flask’s contents after sonication exposure at 
15 s intervals was measured via UV spectroscopy at 355 nm (ε = 26,303 L/mol cm), and 
used as a proxy for the extent of the observed sonochemical activity. All reported results 
represent the mean of three experiments. Evidence of sonoluminescence occurring within 
the T-25 flask contents was observed during sonication and photographed at 30 s exposure 
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time using an Andor iXon X3 Low Light Camera (Figure 3), further indicating the presence of 
acoustic cavitation [20, 21]. 
 
2.5 Cell Sonication Study 
A series of experiments involving the sonication of un-dosed PANC-1 cells were conducted 
to determine an appropriate configuration of ultrasound parameters, namely frequency, 
power and T-25 flask exposure time, for use in the combined treatment study.  
PANC-1 cells were split into T-25 flasks at a seed density of 2 x 106 cells/flask, before 
adding 5 mL/flask supplemented DMEM solution and incubating for 24 hours prior to 
sonication. Each T-25 flask was submerged in 500 mL distilled water (Figure 2) at a starting 
temperature of 35 C and sonicated at one of the six tested frequency-power combinations 
(Section 2.4) for an exposure time of 15 s. Following sonication all flasks were incubated for 
a further 24 hours prior to the measurement of cell death via hemocytometry. Both the 
anchorage independent cells (detached) in suspension with supplemented DMEM solution 
that were deemed dead, and the anchorage dependent cells (adhered) that were deemed 
alive and harvested via trypsinisation, were counted based on a 20 µL sample.  This method 
of cell viability measurement was pre-validated by comparison with a trypan blue exclusion 
assay, and an MTS assay (data not shown) and is generally used in similar areas of in vitro 
research [22, 23, 24]. Hence, the pre-validation demonstrated that the detached cells would 
invariably take up the dye (indicating that they are not viable), while the adhered cells would 
invariably reject the dye (indicating that they are viable). It was therefore deemed that 
comparing the adhered and detached cell counts was appropriate for the investigation. This 
had the added advantage of reducing the amount of cell handling steps, which may have 
altered the observed viability for only the adhered cells. All reported results represent the 
mean and standard deviation of two experiments.  
 
2.6 Combined Treatment Study 
The combined treatment study was designed to investigate the extent of any observed 
synergistic increases in cytotoxic effects of a SDT treatment using sanguinarine and GRE as 
measured relative to the additive cytotoxic effects observed when using either compound 
and ultrasound exposure independently. The study therefore included six experimental 
conditions: un-dosed, not-sonicated (CELLS); un-dosed, sonicated (CELLS+US); dosed, 
not-sonicated (CELLS+SANG, CELLS+GRE); dosed, sonicated (CELLS+SANG+US, 
CELLS+GRE+US). Cell death was measured 24 and 48 hours post-sonication.  
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T-25 flasks of PANC-1 cells were prepared as per the cell sonication study (Section 2.5). 
The un-dosed experiment T-25 flasks (CELLS, CELLS+US) were re-filled with 5 mL/flask 
fresh supplemented DMEM solution. The dosed experiment T-25 flasks (CELLS+SANG, 
CELLS+GRE, CELLS+SANG+US, CELLS+GRE+US) were dosed with sanguinarine or GRE 
diluted in 5 mL/flask supplemented DMEM solution to the appropriate concentrations- 100 
µM sanguinarine and 1 mM GRE. This is equivalent on a mol compound per cell basis to the 
200 µL dosages administered to 4,000 cells/well in the drug screening study. All T-25 flasks 
were incubated for 1 hour prior to sonication. 
The sonicated experiment T-25 flasks (CELLS+US, CELLS+SANG+US, CELLS+GRE+US) 
were sonicated at 500 kHz, 10 W, 15 s, as per the cell sonication study (Section 2.5). The 
non-sonicated experiment T-25 flasks (CELLS, CELLS+SANG) were removed from the 
incubator for the entirety of the sonication experiments. Post-sonication, all T-25 flasks were 
incubated for 24 and 48 hours prior to measurement of cell death in each flask via 
hemocytometry, as per the cell sonication study (Section 2.5). All reported results represent 
the mean and standard deviation of three experiments.  
 
3 Results and Discussion 
3.1 Natural Compound Screening 
The cell viability measurements as taken 24, 48 and 72 hours after dosing with sanguinarine 
and GRE across the narrower range of dosages tested in the second screening are 
presented in Figure 4. Cell viability values were measured relative to an un-dosed control 
cell culture. For both compounds across all time periods the cell viability was observed to 
decrease with increasing dosage, indicating a dose-dependent toxicity for both sanguinarine 
and GRE in the presence of PANC-1 cells. This largely confirms the findings of other 
published works using these compounds at similar dosage levels with other cancer cell lines 
[10, 13], with any minor discrepancies in observed viability measurements likely due to 
differences in the population size of the dosed cell cultures. At low dosages of both 
compounds, cell viability was reduced after 24 hours but increased over the 48- and 72-hour 
observation periods. This trend is reversed at greater dosages of both compounds, where 
the reduction in cell viability was greater after 48 and 72 hours than was observed 24 hours 
after dosing. This is pertinent to the scheduling of the sonication procedure of a combined 
treatment, which should complement the time at which the sonosensitiser is most active. 
Though not specifically tested in this investigation, it is believed this toxicity was caused by 
the same ROS-mediated mechanisms referred to in the existing work relating to these two 
compounds [10, 11, 12, 13]. 
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Based on these findings the dosages of each compound for the combined SDT treatment 
tested in the combined treatment study (Section 3.3) were chosen to be 5 μM sanguinarine 
and 50 μM GRE. These dosages were chosen to correspond to an approximate reduction in 
cell viability of 50% relative to the un-dosed control culture, as determined via linear 
interpolation of the 24-hour data presented in Figure 4. Note these dosages were 
subsequently scaled up in the combined treatment study (100 μM sanguinarine, 1mM GRE) 
to account for both the larger cell culture populations in the T-25 flasks (4,000 cells/well to 
2,000,000 cells/flask), and the increased solvent DMEM volume (200 μL/well to 5 mL/flask). 
 
3.2 Sonication Studies 
3.2.1 Ultrasound Calibration 
The measurements of both the calorimetric power received by the T-25 flask, and tri-iodide 
concentration after 15 s of sonication resulting from the dosimetric test are presented for 
each of the six tested frequency-power configurations in Table 1. For the same incident 
power as set using the amplifier, a greater calorimetric power was observed when sonicating 
at 500 kHz than was observed when sonicating at 1.0 MHz. This suggests that sonication at 
the lower frequency increases the likelihood of more cavitational activity (i.e. higher bubble 
number and stronger collapse intensity) in the flask’s fluid contents, which would augment 
any microbubble-cell interaction in a sonicated cell culture. The observed yield of tri-iodide 
ions in the flasks sonicated at 500 kHz are an order of magnitude greater than those 
observed after sonication at 1.0 MHz, indicating that a greater amount of cavitation-mediated 
ROS production occurs at this lower frequency. This is in agreement with established 
ultrasound theory that relates lower sonication frequencies to a longer rarefaction cycle, and 
increased time in which a cavitation microbubble can collapse- as is necessary for ROS 
production [20]. 
 
Table 1-Ultrasound calibration results, values represent the mean of three measurements. 
Incident Frequency 
(MHz) 
Incident Power 
(W) 
Calorimetric Power 
(W) 
Tri-iodide (I3
-
) 
Concentration; 15 s 
exposure 
(mol dm
-3
) 
0.5 10.0 0.42 1.90 x 10
-6
 
0.5 20.0 0.86 2.56 x 10
-6
 
0.5 30.0 1.37 4.12 x 10
-6
 
1.0 20.0 0.76 1.27 x 10
-7
 
1.0 30.0 1.19 4.56 x 10
-7
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1.0 40.0 1.72 6.84 x 10
-7
 
The observation of sonoluminescence in the T-25 flask contents shown in Figure 3 is a 
further indication of the presence of sonochemical cavitation activity in this system, and can 
be considered as a qualitative validation of the dosimetric results shown in Table 1. More 
specifically, this observation confirms that the sonication transmission efficiency through the 
bulk fluid and T-25 flask is sufficient to generate cavitation activity. Sonolumescence also 
indicates the presence of high-energy bubble collapse, as the power threshold for 
sonoluminescence is higher than sonochemistry [25].  In other words, the sonoluminescence 
occurs with a much higher energy than sonochemsitry.  
 
3.2.2 Cell Sonication 
The cell death measurements resulting from the final un-dosed cell sonication study 
(exposure time of 15 s) as taken 24 hours after sonication for the six tested frequency-power 
configurations are presented in Figure 5. Cell death measurements were taken as the ratio 
of the hemocytometry count of unadhered cells in suspension in each T-25 flask to the sum 
of the counts of unadhered and adhered cells in each T-25 flask. Significant cell death was 
observed across each of the six experiments relative to the non-sonicated control 
experiment. For the same incident power as set using the amplifier, a greater amount of cell 
death was observed when sonicating using the 500 kHz transducer than was observed when 
using the 1.0 MHz transducer. This is in agreement with the finding of the calorimetric test in 
Section 3.2.1. 
It is likely that this cell death is caused by the same combination of sonomechanical and 
sonochemical mechanisms outlined in other published works. The hydrodynamic shearing 
forces and acoustic streaming that occurs around stable cavitation microbubbles, and the 
jetting phenomena caused by collapsing microbubbles, are well-known features of a 
cavitating fluid [20]. These characteristics have been shown to cause significant damage in 
the form of membrane rupture and cell lysis, should the fluid forces be sufficient in 
magnitude [26, 27, 28]. Alternatively, the extreme physical conditions generated during the 
collapse of microbubbles are known to facilitate the production of radical oxygen species 
(ROS), such as peroxyl and hydroxyl radicals and singlet oxygen [20]. Ultrasound-induced 
ROS have been shown to cause cellular damage and cytotoxicity across a number of 
studies, mediating autosis and necrosis via interaction with cell internals [21] and membrane 
damage via peroxidation of the phospholipid bi-layer [2, 29]. 
Plots of these cell death measurements against the calorimetric power and tri-iodide results 
from the ultrasound calibration experiments respectively (Section 3.2.1) are presented in 
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Figure 6. Figure 6a shows a positive correlation between the incident calorimetric power and 
cell death for both frequencies, indicating that the dominant cavitational mechanism involved 
here is power-dependent. Figure 6b shows that a similar extent of cell death was achieved 
by sonication at 1 MHz and 500 kHz despite the much greater yield of ROS (by proxy of the 
tri-iodide measurement) observed at the lower frequency. Considered together, these results 
suggest that the reduction in cell viability resulting from sonication in the absence of a 
sonosensitiser for this experimental setup is predominantly due to sonomechanical effects. 
An appropriate ultrasound frequency-power configuration for the combined SDT treatment in 
the combined treatment study was deemed to be one that minimised direct cell damage (so 
that any synergistic increase can be easily identified), but increased the potential for 
interaction with the sanguinarine and GRE sonosensitisers. Given the reported involvement 
of ROS in the cytotoxic action of both compounds (Section 3.1) and the analysis presented 
here, this configuration was chosen to be 500 kHz; 10 W. 
 
3.3 Combined Treatment Study 
The cell death measurements from the combined treatment study, taken at 24 and 48 hours 
after sonication for the six experiment configurations are presented in Figure 7. Across both 
24- and 48-hour observations, the extent of cell death observed in all dosed and/or 
sonicated experiments exceeded that observed in the un-dosed and non-sonicated control 
experiment (CELLS). Normalising the 24-hour results to account for the baseline cell death 
in the control experiment, the observed cell death in both combined SDT experiments 
(CELLS+SANG+US, CELLS+GRE+US) exceeded the sum of the observed cell deaths for 
the respective isolated experiments (CELLS+US plus CELLS+SANG, and CELLS +US plus 
CELLS+GRE, respectively). This indicates that a synergistic increase in cytotoxic effect was 
observed in the combined SDT experiment for both compounds, with an increase of 6% in 
the sanguinarine treatment and 17% in the GRE treatment, as measured 24 hours after 
sonication. The measurements recorded 48 hours after sonication indicate no increase in the 
combined sanguinarine experiment (CELLS+SANG+US), and an increase (non-synergistic) 
of just 2% in the combined GRE experiment (CELLS+GRE+US). Statistical analysis of the 
24-hour data for both combined treatments relative to the sum of the isolated experiments 
was performed using Student’s t-test. The combined GRE treatment was found to be 
statistically significant for p<0.01, while the sanguinarine SDT treatment was found only to 
be significant for p<0.2.  
The findings of this combined treatment study therefore validate both sanguinarine and GRE 
as effective sonosensitisers for a novel pancreatic cancer SDT treatment. Discrepancies 
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between the trial studies and the isolated experiments of this study with regard to the 
observed cytotoxicity measurements may be noted. The CELLS+SANG; CELLS+GRE 
experiments were more toxic than in the screening study; and the CELLS+US experiment 
less toxic than the sonication study. However, the combined treatment experiments: 
CELLS+SANG+US, CELLS+GRE+US gave toxicity measurements of less than 100% which 
validates the reported findings. Although the relatively modest synergistic increase of the 
sanguinarine-SDT treatment’s cytotoxicity was shown not to be statistically significant here, 
the GRE-SDT treatment demonstrated a substantial increase in toxicity of 24 hours post-
sonication, indicating its strong affinity for a novel anti-cancer treatment with ultrasound-
induced cavitation. It is however worth noting that these effects were observed for a single 
dose of compound with sonication at a single frequency-power configuration- the effect of 
varying these parameters on the magnitude of this synergy has not been investigated as part 
of this work.  
A less severe sonomechanical effect that might explain the synergistic increase in cell death 
of the combined SDT treatment is the phenomenon of ‘sonoporation’. Here the cell 
membrane undergoes a transient permeation due to liquid jets from collapsing microbubbles 
at its surface, allowing an increased uptake of macromolecules from the surrounding fluid [2, 
30]. The increased uptake of the molecules from the surrounding liquid relies on the 
presence of microbubbles produced by ultrasound and can lead to enhanced drug delivery 
[31]. The degree permeability of the membrane is dependent on the applied ultrasonic 
parameters [32] and pore sizes have been reported in the 100s of nanometer range [33]. 
The pore size is likely dependent on the conditions applied and for this mechanism to be 
responsible for the synergistic increases observed here, the chosen sonication frequency-
power configuration would need to generate microbubbles of a particular size relative to the 
PANC-1 cells to allow the necessary ‘controlled’ cell damage. Published work has 
investigated the effect of these ultrasound parameters on bubble size distribution [34], and 
could inform any changes to the present configuration that would enhance this sonoporation 
effect. Though the evidence in Section 3.2.2 suggests that the direct toxicity of the 
ultrasound cavitation alone is due to sonomechanical effects, the synergistic increase in 
toxicity of the combined SDT treatments observed here cannot definitively be attributed to 
these same effects. Though an increased toxicity by this mechanism would be independent 
of the anti-neoplastic method of the compound involved, the ability to increase the effective 
drug uptake would be particularly desirable in the treatment of dense, resistant PDAC 
tumours in later in vivo models.  
Alternatively, the observed synergistic increases could be attributed to a constructive 
interaction of the compounds with the sonochemical effects of acoustic cavitation. Any 
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additional ROS generated by collapsing microbubbles can augment the radically-driven 
pathways from toxic sonosensitisers like sanguinarine and GRE [35, 36]. The radicals 
produced by ultrasound can initiate radically-driven pathways via initial radical attacks on the 
therapeutic agents. The advantages of ultrasonic If this is a prominent mechanism in these 
treatments, the difference in the extent of the synergistic increases is likely due to the 
differing stoichiometry of both treatments as a result of using two different compound 
dosages. It is also worth noting that while sanguinarine is a single chemical compound, the 
GRE used in this investigation is a mixture of several chemical species [13] that may contain 
more than one sonochemically-sensitive component, which might also explain the differing 
extent of the two treatments’ increases in cytotoxicity. 
Where other work has discussed the cytotoxic effects of sonicated systems caused by 
thermal effects [1], the ultrasound setting used in the combined treatment study for a 
sonication exposure time of 15 s was observed to cause a bulk fluid temperature increase of 
just 0.4C during the calorimetric testing. As such, it is unlikely that the synergistic increase 
in cytotoxicity observed here is the result of bulk thermal effects. The significant findings of 
this investigation nonetheless warrant further development of these novel SDT treatments, 
with a view to optimising the two components to maximise the extent of the synergistic cell 
death effects. Progressing the treatment towards in vivo and clinical trials should attempt to 
achieve this optimum within the constraints of using compound dosages and ultrasound 
exposure levels that are deemed safe for human therapeutic use. 
 
4 Conclusions 
The present work aimed to evaluate the suitability of two novel naturally-derived anti-cancer 
agents, sanguinarine and ginger root extract (GRE), to be used as sonosensitisers in a 
sonodynamic therapy treatment for human pancreatic cancer. The dose-dependent 
cytotoxicity of both compounds reported in other works was confirmed here in the presence 
of in vitro PANC-1 cells. A range of six ultrasound power-frequency configurations were 
tested for the ability induce acoustic cavitation in this experimental setup, and suitability for a 
SDT treatment when combined with the two compounds. It was found that the cell damage 
and death resulting directly from the ultrasound-induced cavitation was likely due to 
sonomechanical effects, rather than sonochemical effects.  
The main study involving the two combined SDT treatments found both sanguinarine and 
GRE to act as sonosensitisers, and cause a synergistic increase in the observed cell death 
relative to the additive effects of the compound and ultrasound alone. The GRE SDT 
experiment was found to cause a statistically significant synergistic increase in cell death of 
  
13    
17%, indicating its strong suitability for use in this developing treatment. Further work should 
aim to determine the primary mechanism by which the enhanced toxicity of both compounds 
is achieved, with a view to maximising the extent of the increase in toxicity by manipulation 
of the ultrasound parameters. 
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List of Figures 
Figure 1. Novel anti-cancer agent schematics (sigmaaldrich.com). 1a shows sanguinarine; 
1b shows [6]-shogaol; 1c shows [6]-gingerol. 
 
Figure 2. Sonication equipment configuration schematic, drawn as used in the combined 
SDT study. A distance of 25 mm between the T-25 flask and the transducer plate was 
maintained for all studies involving sonication. 
 
Figure 3. Photographic evidence of sonoluminescence observed during sonication (amplifier 
frequency-power configuration: 500 kHz; 10.0 W). 3a shows the T-25 flask prior to 
sonication; 3b shows the T-25 flask during sonication, with sonoluminescence present in the 
surrounding distilled water and within the flask itself. 
 
Figure 4. Results of second screening study. 4a and 4b show the cell viability measurements 
from the MTS assay kit across all three days of observation, for sanguinarine and GRE 
respectively. All values represent the mean and standard deviation of four measurements. 
 
Figure 5. Results of cell sonication study. Cell death as measured via hemocytometry 24 
hours after 15 s sonication is presented for each of the six amplifier frequency-power 
configurations. All values represent the mean and standard deviation of two measurements. 
 
Figure 6. Comparison of the cell sonication results with ultrasound calibration results. Figure 
6a indicates that cell death is a function of incident power. Figure 6b indicates that across 
the two frequencies cell death is not a strong function of present ROS concentration. 
 
Figure 7. Results of the synergistic effect study. 100 μM sanguinarine, 1 mM GRE.  Figure 
7a shows the cell death measurements as recorded 24 h after sonication at 500 kHz, 10 W. 
7b shows the cell death measurements as recorded 48 h after sonication at 500 kHz, 10 W. 
All values represent the mean and standard deviation of three measurements. 
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Highlights 
 
 Anti-cancer properties of sanguinarine and ginger root extract (GRE) confirmed. 
  
 Both compounds used successfully as sonosensitisers with in vitro PANC-1 cells. 
 
 GRE-Sonodynamic therapy treatment achieved 17% synergistic toxicity increase. 
 
 Sanguinarine-Sonodynamic therapy treatment reached 6% synergistic toxicity 
increase. 
 
